Secondarily, we evaluated the dynamics of these EGFR mutations with respect to the primary tumor, the presence of the T790M mutation and its relationship with drug resistance to TKIs and analyzed, by NGS, molecular alterations in the cfDNA of patients with NSCLC undergoing TKI treatment that have unexplained acquired resistance. Here, EGFR is linked to non-small cell lung carcinoma.